Basal Cell Carcinoma (Therapy)

New Drugs for Skin Cancer Therapy Studied

Published in Cancer Weekly, March 15th, 1999

Ontogeny, Inc., Cambridge, Massachusetts, announced that it has established an agreement with the University of California San Francisco (UCSF) to evaluate the therapeutic potential of novel compounds for the treatment of basal cell carcinoma (BCC).

The program will use a model of BCC developed at UCSF. A team, headed by Ervin Epstein, MD, UCSF clinical professor of dermatology, will assess the safety and efficacy of a variety of novel pharmacological agents in treating the disease. Ontogeny will evaluate its lead compounds to determine in vivo activity against this cancer. Compounds demonstrating efficacy in this model will move forward in the company's clinical...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1999-03-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry